News
AXDX
1.080
+23.11%
0.203
12 Health Care Stocks Moving In Tuesday's Intraday Session
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by to $ during Tuesday's regular session. The company's market cap stands at $ million. As per the news, the Q1 earnings report came out 4 days ago. Losers Dare Bioscience and American Oncology Network.
Benzinga · 12h ago
Weekly Report: what happened at AXDX last week (0513-0517)?
Weekly Report · 1d ago
Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting
TipRanks · 05/13 20:23
Accelerate Diagnostics, Inc. Q1 2024 Financial Report: Condensed Consolidated Balance Sheets and Management's Discussion and Analysis of Financial Condition and Results of Operations
Press release · 05/13 12:17
Weekly Report: what happened at AXDX last week (0506-0510)?
Weekly Report · 05/13 10:30
CORRECTED-(OFFICIAL)- BRIEF-Accelerate Diagnostics Q1 Sales USD 2.9 Million (May 8)
Reuters · 05/10 21:46
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q1 2024
Accelerate Diagnostics reported earnings per share of -88 cents for the first quarter of 2024. The company reported revenue of $2.92 million. This was 2.63% worse than the analyst estimate for revenue in the same period. Accelerate Diagnostic reported results for the second quarter of 2016.
Investorplace · 05/09 01:57
Accelerate Diagnostics GAAP EPS of -$0.88 misses by $0.16, revenue of $2.9M misses by $0.1M
Seeking Alpha · 05/08 20:51
*Accelerate Diagnostics 1Q R&D Expenses $5.2M >AXDX
Dow Jones · 05/08 20:46
ACCELERATE DIAGNOSTICS INC: QTRLY SHR LOSS $0.88
Reuters · 05/08 20:42
ACCELERATE DIAGNOSTICS REPORTS PRELIMINARY FIRST QUARTER 2024 FINANCIAL RESULTS
Reuters · 05/08 20:42
ACCELERATE DIAGNOSTICS Q1 NET INCOME USD -17 MILLION
Reuters · 05/08 20:42
*Accelerate Diagnostics 1Q Loss/Shr 88c >AXDX
Dow Jones · 05/08 20:42
*Accelerate Diagnostics 1Q Loss $17M >AXDX
Dow Jones · 05/08 20:42
Press Release: Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results
Accelerate Diagnostics reports Preliminary First Quarter 2024 Financial Results. The company installed its first pre-clinical trial site for the Accelerate Wave system with Gram-Negative Positive Blood Culture samples in a clinical microbiology lab. The first quarter ended March 31, 2024.
Dow Jones · 05/08 20:42
Press Release: Accelerate Diagnostics Reports -3-
Cost of sales and expenses: Total costs and expenses are more than $10 million. Gross profit is less than $1 million. The company has a net loss of $1.7 million for the quarter. The company's net loss includes a loss on sale of shares and a loss from operations.
Dow Jones · 05/08 20:42
*Accelerate Diagnostics 1Q Sales $2.92M >AXDX
Dow Jones · 05/08 20:42
Press Release: Accelerate Diagnostics Reports -2-
Accelerate Diagnostics, Inc. Is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate PhenoTest(R) system and Accelerate Wave system combine several technologies to reduce the time clinicians must wait to determine optimal antibiotic therapy for deadly infections. The company's results may differ from those expected.
Dow Jones · 05/08 20:42
More
Webull provides a variety of real-time AXDX stock news. You can receive the latest news about Accelerate Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.